

Consolidated Financial Results for the First Quarter of Fiscal Year 03/2012

Consolidated Subsidiaries: 3

Kissei Shoji Co., Ltd. / Kissei Comtec Co., Ltd. / Hashiba Technos Co., Ltd.

| Consolidated | First Quarter of Fiscal Y03/2011 Apr. 2010 - Jun. 2010 | | First Quarter of Fiscal Y03/2012 Apr. 2011 - Jun. 2011 | | | YoY |
|--|---|--------|---|-------------|--------|--------|
| | Mil. of US\$ | Ratio | Mil. of US\$ | Mil. of Yen | Ratio | |
| Net Sales | 196.5 | 100.0% | 191.7 | 15,473 | 100.0% | -2.4% |
| Cost of Sales | 59.2 | 30.1% | 66.9 | 5,395 | 34.9% | 12.9% |
| Gross Profit | 137.3 | 69.9% | 124.9 | 10,077 | 65.1% | -9.1% |
| Selling, General and Administrative Expenses | 111.7 | 56.8% | 103.5 | 8,353 | 54.0% | -7.3% |
| Operating Income | 25.6 | 13.0% | 21.4 | 1,723 | 11.1% | -16.6% |
| Net Income | 15.4 | 7.9% | 16.6 | 1,337 | 8.6% | 7.3% |

Note: US dollar amounts are translated at the rate of ¥80.7 = US\$1.

Financial Forecasts for Annual 03/2012

| Consolidated | Results of Annual 03/2011 Apr. 2010 - Mar. 2011 | | | Forecasts for Annual 03/2012 Apr. 2011 - Mar. 2012 | | | YoY |
|---|--|-------------|--------|---|-------------|--------|-------|
| | Mil. of US\$ | Mil. of Yen | Ratio | Mil. of US\$ | Mil. of Yen | Ratio | |
| Net Sales | 797.9 | 64,393 | 100.0% | 800.5 | 64,600 | 100.0% | 0.3% |
| Cost of Sales | 278.8 | 22,498 | 34.9% | 273.9 | 22,100 | 34.2% | -1.8% |
| Gross Profit | 519.1 | 41,895 | 65.1% | 526.6 | 42,500 | 65.8% | 1.4% |
| Selling, General and Administrative Expenses | 439.1 | 35,432 | 55.0% | 446.1 | 36,000 | 55.7% | 1.6% |
| Operating Income | 80.1 | 6,463 | 10.0% | 80.5 | 6,500 | 10.1% | 0.6% |
| Net Income | 49.6 | 4,004 | 6.2% | 57.0 | 4,600 | 7.1% | 14.9% |

¥80.7 = US\$1

Trends in Business Performance

(Millions of Yen except Number of Employees)

| Consolidated | 03/2008 | 03/2009 | 03/2010 | 03/2011 | 03/2012 Forecasts |
|----------------------------------|---------|---------|---------|---------|----------------------|
| Net Sales | 61,480 | 64,535 | 62,178 | 64,393 | 64,600 |
| Operating Income | 4,269 | 6,393 | 6,584 | 6,463 | 6,500 |
| (% of Net Sales) | 6.9 | 9.9 | 10.6 | 10.0 | 10.1 |
| Extraordinary Gain or Loss | 213 | 2,815 | 604 | 604 | - |
| Net Income | 2,325 | 2,061 | 4,371 | 4,004 | 4,600 |
| (% of Net Sales) | 3.8 | 3.2 | 7.0 | 6.2 | 7.1 |
| R&D Expenses | 11,361 | 11,556 | 10,786 | 12,037 | 11,900 |
| (% of Net Sales) | 18.5 | 17.9 | 17.3 | 18.7 | 18.4 |
| Depreciation and Amortization | 3,862 | 3,709 | 3,233 | 2,809 | 2,770 |
| Capital Investment | 2,460 | 1,414 | 2,037 | 1,322 | 2,010 |
| Export Value | 1,953 | 2,917 | 1,746 | 2,647 | 1,640 |
| Number of Employees | 1,844 | 1,870 | 1,920 | 1,911 | - |

< Years ended / ending March 31 >

Trends in Main Product Sales

(Millions of Yen)

| Products | 03/2010 Results | 03/2011 Results | 03/2011 1Q Results | 03/2012 1Q Results | 03/2012 Forecasts |
|---------------------------|--------------------|--------------------|-----------------------|-----------------------|----------------------|
| URIEF | 8,706 | 9,723 | 2,276 | 2,666 | 11,060 |
| GLUFAS | 4,911 | 5,160 | 1,322 | 1,194 | 5,100 |
| GLUBES | — | — | — | — | 540 |
| SALAGEN | 828 | 990 | 250 | 262 | 1,150 |
| EPOETIN ALFA BS INJECTION | — | 1,251 | 99 | 580 | 3,680 |
| BEZATOL | 8,495 | 7,459 | 2,002 | 1,846 | 6,890 |
| UTEMERIN | 4,876 | 4,627 | 1,131 | 1,052 | 4,400 |
| XANBON | 2,030 | 1,697 | 446 | 384 | 1,530 |
| RIZABEN Eye Drops | 2,384 | 2,665 | 373 | 356 | 2,140 |
| RIZABEN | 1,909 | 1,911 | 466 | 417 | 1,830 |
| DOMENAN | 349 | 312 | 86 | 67 | 280 |
| CABASER | 3,092 | 2,568 | 726 | 572 | 2,310 |
| FRAGMIN | 1,261 | 837 | 249 | 150 | 650 |
| RYSMON TG | 1,050 | 874 | 244 | 173 | 740 |
| ZOLADEX 1.8mg Depot | 731 | 805 | 177 | 156 | 800 |
| FULSTAN | 617 | 647 | 173 | 166 | 630 |

< Years ended / ending March 31 >